Antirrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: Electrophysiological determinants of enhanced conversion efficacy

Circulation

Volumn 96, Issue 12, 1997, Pages 4298-4306

  Stambler, Bruce S ^a,c   Wood, Mark A ^b   Ellenbogen, Kenneth A ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA BOSTON HEALTHCARE SYSTEM   (United States)

Author keywords

Action potentials; Antiarrhythmia agents; Electrophysiology; Fibrillation

Indexed keywords

IBUTILIDE FUMARATE; PLACEBO; PROCAINAMIDE; ANTIARRHYTHMIC AGENT; IBUTILIDE; SULFONAMIDE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SCREENING; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART MUSCLE POTENTIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; COMPARATIVE STUDY; ELECTROPHYSIOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTROPHYSIOLOGY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROCAINAMIDE; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0031283294     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.12.4298     Document Type: Article

References (40)

1. Feld GK, Venkatesh N, Singh BN. Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction. Circulation. 1986;74:197-204.
2. Wu KM, Huffman BF. Effect of procainamide and N-acetylprocainamide on atrial flutter: studies in vivo and in vitro. Circulation. 1987;76:1397-1408.
3. Okumura K, Waldo AL. Effects of N-acetylprocainamide on experimental atrial flutter and atrial electrophysiologic properties in conscious dogs with sterile pericarditis: comparison with the effects of quinidine. J Am Coll Cardiol. 1987;9:1332-1338.
4. Feld GK, Venkatesh N, Singh BN. Effects of N-acetylprocainamide and recainam in the pharmacologic conversion and suppression of experimental canine atrial flutter: significance of changes in refractoriness and conduction. J Cardiovasc Pharmacol. 1988;11:573-580.
5. Rensma PL, Allessie MA, Lammers WJE, Bonke FIM, Schalij MJ. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res. 1988;62:395-410.
6. Spinelli W, Hoffman BF. Mechanisms of termination of reentrant atrial arrhythmias by class I and III antiarrhythmic agents. Circ Res. 1989;65:1565-1579.
7. Inoue H, Yamashita T, Nozaki A, Sugimoto T. Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of refractory period and depression of conduction to excitable gap. J Am Coll Cardiol. 1991;18:1098-1104.
8. Schoels W, Yang H, Gough WB, El-Sherif N. Circus movement atrial flutter in the canine sterile pericarditis model: differential effects of procainamide on the components of the reentrant pathway. Circ Res. 1991;68:1117-1126.
9. Kirchhof C, Wijffels M, Brugada J, Planellas J, Allessie MA. Mode of action of a new class 1C drug (ORG 7797) against atrial fibrillation in conscious dogs. J Cardiovasc Pharmacol. 1991;17:116-124.
10. Wang Z, Page P, Nattel S. The mechanism of flecainide's antiarrhythmic action in experimental atrial fibrillation. Circ Res. 1992;71:271-287.
11. Boyden PA, Graziano JN. Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol. J Cardiovasc Electrophysiol., 1993;4:266-279.
12. Wang J, Bourne G, Wang Z, Villemaire C, Talajic M, Nattel S. Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation: the importance of use-dependent effects on refractoriness. Circulation. 1993;88:1030-1044.
13. Fei H, Frame LH. d-Sotalol terminates reentry by two mechanisms with different dependence on the duration of the excitable gap. J Pharm Exp Ther. 1996;277:174-185.
14. Cha Y, Wales A, Wolf P, Shahrokni S, Sawhney N, Feld GK. Electrophysiologic effects of the new class III antiarrhythmic drug dofetilide compared to the class IA antiarrhythmic drug quinidine in experimental canine atrial flutter: role of dispersion of refractoriness in antiarrhythmic efficacy. J Cardiovasc Electrophysiol. 1996;7:809-827.
15. Feld GK. Pharmacological control of experimental atrial arrhythmias: significance of prolonging excitation wavelength. In: Singh BN, Wellens HJJ, Hiraoka M, eds. Electropharmacological Control of Cardiac Arrhythmias to Delay Conduction or to Prolong Refractoriness? Mount Kisco, NY: Futura Publishing Co; 1994:265-277.
16. Allessie MA. Reentrant mechanisms underlying atrial fibrillation. In: Zipes DP, Jalife J, eds. Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia, Pa: WB Saunders Co; 1995:562-566.
17. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. The Sicilian Gambit: a new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation.. 1991;84:1831-1851.
18. Buehanan LV, Kabell GG, Gibson JK. Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents. J Cardiovasc Phartnacol. 1995;25:539-544.
19. + current in guinea pig ventricular cells. J Pharm Exp Ther. 1992;262:99-108.
20. kr) in AT-1 cells. Circulation. 1995;91:1799-1806.
21. Stambler BS, Wood MA, Ellenbogen KA, Perry KT, Wakefield LK, VanderLugt JT, and the Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;94:1613-1621.
22. Ellenbogen KA, Stambler BS, Wood MA, Sager PT, Wesley RC, Meissner MD, Zoble RG, Wakefield LK, Perry KT, VanderLugt, for the Ibutilide Investigators. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a doseresponse study. J Am Coll Cardiol. 1996;28:130-136.
23. Volgman AS, Stambler BS, Kappagoda C, Carberry PA, Dunn GH, Perry KT, VanderLugt JT, Kowey PR. Comparison of intravenous ibutilide versus procainamide for the rapid termination of atrial fibrillation or flutter. PACE. 1996;19:608. Abstract.
24. Rosen MR, Gelband H, Hoffman BF. Canine electrocardiographic and electrophysiologic changes induced by procainamide. Circulation. 1972;46:528-536.
25. Hoffman BF, Rosen MR, Wit AL. Electrophysiology and pharmacology of arrhythmias, VII: cardiac effects of quinidine and procainamide. Am Heart J. 1975;90:117-122.
26. Wells JL, Karp RB, Kouchoukos NT, MacLean WH, James TN, Waldo AL. Characterization of atrial fibrillation in man: studies following open heart surgery. PACE. 1979;1:426-438.
27. Fenster PE, Comess KA, Marsh R, Katzenberg C, Hager WD. Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. Am Heart J. 1983;106:501-504.
28. Halpern SW, Ellrodt G, Singh BN, Mandel WJ. Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm. Br Heart J. 1980;44:589-595.
29. Madrid A, Moro C, Marin-Huerta E, Mestre JL, Novo L, Costa A. Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. Eur Heart J. 1993;14:1127-1131.
30. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial fibrillation in the Wolff-Parkinson-White Syndrome by procainamide and propafenone. J Am Coll Cardiol. 1990;16:1408-1414.
31. Frame LH, Simson MB. Oscillations of conduction, action potential duration, and refractoriness: a mechanism for spontaneous termination of reentrant tachycardias. Circulation. 1988; 78:1277-1287.
32. Ortiz J, Igarashi M. Gonzalez HX, Laurita K, Rudy Y, Waldo AL. Mechanism of spontaneous termination of stable atrial flutter in the canine sterile pericarditis model. Circulation. 1993;88:1866-1877.
33. Guo GBF, Ellenbogen KA, Wood MA, Stambler BS. Conversion of atrial flutter by ibutilide is associated with increased atrial cycle length variability. J Am Coll Cardiol. 1996;27:1083-1089.
34. Inoue H, Matsuo H, Takayanagi K, Murao S. Clinical and experimental studies of the effects of atrial extrastimulation and rapid pacing on atrial flutter cycle: evidence of macro-reentry with an excitable gap. Am J Cardiol. 1981;48:623-631.
35. Della Bella P, Marenzi G, Tondo C, Cardinale D, Giraldi F, Lauri G, Guazzi M. Usefulness of excitable gap and pattern of resetting in atrial flutter for determining reentry circuit location. Am J Cardiol. 1991;68:492-497.
36. Stambler BS, Wood MA, Ellenbogen KA. Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration: evidence of a fully excitable gap in the reentrant circuit. J Am Coll Cardiol. 1996;27:453-441.
37. Konings KTS, Kirchhof CJHJ, Smeets JRLM, Wellens HJJ, Penn OC, Allessie MA. High-density mapping of electrically induced atrial fibrillation in humans. Circulation. 1994;89:1665-1680.
38. Lammers WJEP, Allessie MA, Rensma PL. The use of fibrillation cycle length to determine spatial dispersion in electrophysiological properties and to characterize the underlying mechanisms of fibrillation. New Trends Arrhythmias. 1986;2:109-112.
39. Moe GK. On the multiple wavelet hypothesis of atrial fibrillation. Arch Int Phamacodyn Ther. 1962;140:183-188.
40. Buchanan LV, LeMay RJ, Gibson JK. Comparison of the class III agents d,l-sotalol HCl and ibutilide fumarate for atrial reverse use dependence and antiarrhythmic effects. PACE. 1996;19:687. Abstract.